Wayne Shaw
Johnson & Johnson (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Pancreatic function and diabetes, Diabetes Management and Research, Heart Failure Treatment and Management, Bipolar Disorder and Treatment
Most-Cited Works
- → Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes(2017)7,624 cited
- → Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials(2018)634 cited
- → Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events(2017)500 cited
- → Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus(2018)477 cited
- → Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial(2013)333 cited
- → Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes(2014)236 cited
- → Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( CANVAS‐R ): A randomized, placebo‐controlled trial(2017)165 cited
- → Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus(2019)160 cited
- → A Double‐Blind, Placebo‐Controlled, Dose‐Response Study of the Effectiveness and Safety of Enalapril for Children with Hypertension(2002)152 cited
- → Deposit Insurance and Wealth Effects: The Value of Being "Too Big to Fail"(1990)148 cited